FIGURE 1.

Detection rate of genomic alterations in cfDNA among patients with brain tumors (N = 135). A, According to tumor diagnosis. B, According to WHO‐grades. ³⁵ The rate of characterized alteration in grade III/IV vs grade II tumors was 23% vs 6% (P = .20). Note that grade II is sum of diffuse astrocytoma and the oligodendroglioma; grade III is sum of anaplastic oligodendroglioma and anaplastic astrocytoma. C, According to presence of temozolomide with concurrent radiotherapy (TMZ + RT) prior to blood draw for cfDNA sequencing. The rate of characterized cfDNA alteration in patients with no prior TMZ + RT vs those whose analyzed after TMZ + RT is 2.9% vs 27% (P = .003). cfDNA, cell‐free DNA; TMZ + RT, temozolomide with concurrent radiation therapy; VUS, variant of unknown significance; WHO, World Health Organization